DEXIN

DEXIN, founded in 2011, is the first company in China's medical imaging artificial intelligence field to obtain FDA and CFDA certification. The core entrepreneurial team members graduated from well-known domestic universities such as Tsinghua University and Peking University, and have overseas education and multidisciplinary research backgrounds from institutions like Stanford University, the University of Pittsburgh, and Carnegie Mellon University. The company has independently developed internationally leading AI+ technology based on intelligent geometry and deep learning, providing clinical imaging system solutions for early screening, auxiliary diagnosis, preoperative planning, postoperative evaluation, and follow-up tracking for various diseases including pulmonary, fundus, cardiovascular, breast, liver, kidney, and gastrointestinal conditions. The company has undertaken national and provincial-level scientific projects multiple times, been granted numerous national intellectual property rights, and received tens of millions in Series A funding from Tsinghua Qihang. Its products are already in use in over a hundred renowned hospitals both domestically and internationally, such as 301 Hospital, Xiehe Hospital, Huadong Hospital, Huaxi Hospital, Guangdong Medical Affiliated Hospital, and Xijing Hospital. It is currently applying for the first batch of CFDA Class III certifications for medical artificial intelligence and U.S. FDA Class III certification while actively expanding into overseas markets.